

IMPACT OF COVID-19 ON MYOCARDIAL INFARCTION: A NARRATIVE REVIEW*¹Mohamed Said Mohamud, ¹Bo Yang and ¹Yahya Adullaahi Ali¹Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, Hubei (430060), China.

*Corresponding Author: Dr. Mohamed Said Mohamud

Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, Hubei (430060), China.

Article Received on 22/04/2021

Article Revised on 12/04/2021

Article Accepted on 02/05/2021

ABSTRACT

SARS (Severe Acute Respiratory Syndrome) is a form of acute respiratory syndrome. When Coronavirus 2 (SARS-CoV-2) was exposed to cause extreme respiratory distress syndrome at the end of 2019, it drew worldwide interest. Although it mainly influences the respiratory system, research proposes that it also disturbs other organ systems in the human body. Myocardial cardiogenic shock, systolic heart failure, acute coronary syndrome, infarction, life-threatening arrhythmias are all possible cardiac manifestations. Myocardial infarction is becoming more widely accepted as a barrier of Coronavirus-19, and it can occur as a result of either overactive host immune response or a direct viral damage. The analysis is made using a clinical exam, non-invasive imaging trials, laboratory findings, clear history much as most etiologies. The cardiac MRI is chosen imaging modality when it is available. If the condition is still unclear, an endomyocardial biopsy can be done. The current management is primarily positive, with the possibility of including treatments such as steroids, remdesivir and convalescent plasma, which are prescribed for acute COVID-19 illness. Advanced artificial circulatory support systems should be addressed in the case of refractory and cardiogenic shock, life-threatening arrhythmias that occur during surgical treatment. Finally, early detection and aggressive response are critical to lowering morbidity and mortality. Since learning more about COVID-19 disease and its related heart problems, the management approach is likely to change.

KEYWORDS: COVID-19, heart failure, myocardial infarction, coronavirus.**1.1 INTRODUCTION**

COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; earlier mentioned to as 2019-nCoV).^[1] Patients with coronavirus typically present with symptoms and signs of respiratory tract infection, but cardiac manifestations, including signs of myocardial injury, are common. Patients infected with the virus SARS-CoV-2 and its clinical disease COVID-19 are often minimally symptomatic or asymptomatic. More severe presentations include pneumonia and acute respiratory distress syndrome.^[2] In some patients, the heart may be affected, and this can occur in individuals with or without a prior cardiovascular diagnosis. Stress cardiomyopathy, ischemic injury, hypoxic injury (caused by epicardial coronary artery disease or cardiac microvascular disruption), and systemic inflammatory response syndrome are all possible causes of myocardial injury, as measured by an elevated troponin level, in COVID-19 patients (cytokine storm).^[3] Patients with an elevated troponin level are more likely to have symptoms and signs of an acute coronary syndrome. The myocardial infarction, known as heart attack, happens when blood supply to a portion of the heart is stopped or reduced, resulting in injury to the heart muscle. Stiffness or Chest pain is the most frequent sign, which may

spread to the arm, spine, shoulder jaw and throat. It mostly happens in the left side or middle of the chest which lasts for several minutes. It's possible that the pain would feel like heartburn at times. Shortness of breath, fatigue, dizziness, faintness, a cold sweat, or exhaustion are some of the other symptoms.^[4]

1.2 Rates of Myocardial Infarction Hospitalization during Pandemic

Many surveys have shown that after the pandemic, the rate of hospitalization for acute myocardial infarction (MI) and admissions for most diagnoses declined by up to 50%. A research from Northern California compared hospitalization rates for acute non-ST-elevation MI [NSTEMI] and MI (ST-elevation MI [STEMI]) before and after March, 2020, when the first COVID-19 death was recorded in Northern California.^[5] These figures were comparable to figures from the same timeframe in 2019. In 2020, the rate of acute MI hospitalization was slightly lower than in 2019, indicating that the decline was not due to seasonal variation. A study from Italy compared admissions for acute MI to coronary care units from March 12th to 19th in 2020 with those during the equivalent week in 2019. There was a 49.4 percent reduction ($p < 0.001$ percent), and the reduction was significant for both STEMI and NSTEMI. The STEMI

case fatality rate was higher, comparing 2020 with 2019 (risk ratio 3.3, 95% CI 1.7-6.6).^[6]

A major database analysis conducted in England compared hospital charges for acute coronary syndromes from mid-February to the end of March 2020 to the weekly average in 2019 (3017 per week).^[7] By the end of March 2020, the weekly average of patients admitted to hospitals in England with ACS had decreased significantly (1813 per week; 40% reduction) relative to the weekly average in 2019. The trend was partially reversed by the end of May, 2020 (2522 per week; 16 percent reduction).^[8] Although the decline in hospital admissions was seen across all types of ACS (e.g., STEMI, NSTEMI, unstable angina, and MI of unknown type), it was most pronounced for those with NSTEMI. Possible explanations for the decreased hospitalization rate include patient fear of being infected if hospitalized (avoidance of medical care) and a redistribution of health care. Perhaps consequent to the decrease in hospitalization rates, at least three studies have documented a decline in the number of the acute coronary disease patients referred for percutaneous coronary mediation.^[9]

1.3 Epidemiology

The occurrence of coronary artery disease (CAD) in particular, and cardiovascular disease in general, varies by population. Thus, there is a wide variety of prevalent CAD among patients diagnosed with COVID-19. Rates ranging from 4.2 to 25% have been published, with the majority of series coming from China.^[10] The proportion of patients or deaths admitted to intensive care units is high. Myocardial damage (as shown by an increase in cardiac troponin levels) occurs at a variable rate in hospitalised patients with COVID-19, ranging from 7% to 28%. Coronary artery disease sometimes manifests as myocardial infarction. In 2004, the World Health Organization reported that ischemic heart disease caused 12.2 percent of global deaths, it is the second important cause of expiry in high- and middle-income states, and the second important cause of respiratory illness in low- and middle-income states.^[11]

COVID-19 can induce viral pneumonia, as well as other cardiovascular issues. In early trials in China, 32 percent to 46 percent of patients admitted with COVID-19 had

underlying disorders such as hypertension (15 percent to 31 percent), cardiovascular disease (14.5 percent to 15 percent), and diabetes (10 percent -20 percent).^[12] Hypertension, coronary and cerebrovascular disorder, and diabetes were found to be 17.1 percent, 16.4 percent, and 9.7 percent, respectively, in a meta-analysis of 6 COVID-19 trials.^[13] The occurrence of cardiovascular disease ranged greatly depending on the research size of coronavirus populations, varying in a study of 99 coronavirus patients is 40% to 80% in another study of coronavirus patients. In major trials with more than 1000 COVID-19 patients, 4 to 2 percent were found.^[14] Male gender, old age, and hypertension, diabetes mellitus, coronary disorders, and mental illness, as well as risks of heart failure, cardiomyopathy, and severe cardiac injury are associated with mortality in all coronavirus patients.^[15] Persons with heart disease had a mortality rate of 10.5 percent higher than the average death rate of 2.3 percent in a wide series of 44,672 coronavirus patients. The highest death rate was linked to the simultaneity of coronary heart failure and myocardial damage.^[16]

1.4 Causes and Risk Factors

The risk factors of myocardial infarction heavy smoking, older age, diabetes, elevated blood, cholesterol levels, pressure, and high-density lipoprotein levels are the most common risk factors for myocardial infarction.^[17] Male gender, poor levels of physical activity, a previous family background, alcohol consumption and obesity are both risk factors for myocardial infarction. The Framingham Risk Score, for example, includes risk factors for myocardial disease (Figure 1). Men are at a greater danger of evolving cardiovascular disease than women at any given age. High cholesterol levels, particularly high-density lipoprotein and triglycerides are considered to be risk factors.^[18] The most significant risk factor for myocardial infarction is cigarette smoking (including secondhand smoke). Coronary artery disease tends to be caused by smoking in about 36% of cases and obesity in 20% of cases. 7–12 percent of cases are attributed to a lack of physical exercise. The causes related to stress like work stress accounts for around 3% of cases and persistent higher level of stress is among the less frequent causes.^[19]




Figure 1. Potential Risks of SARC-CoV-2 and Cardiovascular Complications.

The myocardial infarction's role is controversial in saturated fat.^[20] In some research, eating saturated fat rather than polyunsaturated fat has been linked to a lower risk of myocardial infarction, although other studies have found no evidence that decreasing dietary saturated fat or increasing polyunsaturated fat consumption disturbs heart attack possibility. Dietary saturated fatty acid does not seem to have a direct impact on blood cholesterol, so there may be no need for dietary cholesterol guidelines. Tran's fats tend to raise the risk of heart disease. Acute and chronic consumption of large amounts of alcoholic beverages (3–4 or more a day) raises the possibility of a heart attack.^[21]

The medical history of coronary heart disease or myocardial infarction raises the person's risk of myocardial infarction. Genome-wide association analyses find 27 hereditary mutations linked with increased myocardial infarction risk.^[22] MI's strongest correlation was detected with chromosome 9 on locus 21's short arm p, which includes CDKN2A and 2B genes, whereas the SNPs involved are within a non-coding region. Both of these variations are in areas not historically involved in coronary heart disease. The genes having an association with MI include MIA3, 2B, PCSK9, PHACTR1, WDR12, TCF21, LPA, SMAD3, MRAS, MTHFDSL, CDKN2A, SORT1, ZC3HC1, PDGF0, KCNE2, APOA5, ABO, COL4A1, ADAMTS7, HHIP1, MNF1ASM283, RAS1, SNF8, SMG6, LDLR, MRPS6, and SLC5A3.^[23]

With low socioeconomic standing, low physical activity, and increasing age, the likelihood of a myocardial infarction rises. Morning heart problems tend to be more frequent, particularly between the hours of 6 a.m. and noon.^[24] Shift work is also linked to an increased risk of

MI. According to one study, the start of daylight-saving time is associated with a rise in heart attacks.^[25] Women which use combination oral contraceptive pills have a slightly higher risk of myocardial infarction, particularly when other risk issues are present. Endometriosis is a known risk factor in women under the age of 40 years.^[26] Air contamination is another significant danger that can be mitigated. MI and other sudden cardiovascular incidents have been linked to short-term exposure to air pollutants such as nitrogen dioxide, sulphur dioxide and carbon monoxide.^[27]

1.5 Effect of COVID-19 on Cardiovascular System

COVID-19 is thought to have internal and external effects on the cardiovascular system, including the heart.^[28] Direct myocardial damage from hypoxemia or hemodynamic derangement, tension cardiomyopathy, microvascular impairment, autoimmune myocarditis or thrombosis attributable to systemic inflammation or hypercoagulability that can also destabilize coronary artery plaques, are all potential mechanisms of cardiovascular injury. Infections such as pneumonia and influenza have been linked to a sixfold elevated risk of acute MI. Patients with extreme COVID-19, such as those that have a high fever or are hypoxic from lung disease, can need a substantial increase in cardiac activity.^[29] Patients with obstructive CAD can experience type II myocardial ischemia as a result. COVID-19 can increase the risk of acute MI, according to some studies (Figure 2). The clinical impact of SARS-CoV-2 infection will, across a population, be greater in those with prior disease and increasing age. In one study, patients with prior cardiovascular disease made up 22.7 percent of all fatal cases, and the case fatality rate was 10.5 percent.^[30]




Figure 2. Relationship of COVID-19 and Myocardial Infarction.

1.6 Association between Baseline CVD and COVID-19

There is substantial evidence of an association between cardiovascular disease (CVD) risk factors of hypertension, diabetes, prior CAD, and the severity and risk of coronavirus infection. The Chinese studies reports, 72,314 cases (44,672 confirmed) reported by February 11, 2020 were reviewed.^[31] The basic death rate was 2.3 percent. For age over 80, the case fatality rate was 14.8 percent. History of CHD was present in 4.2 percent of all cases, but in 22.7 percent of fatal cases. Another report evaluated 1099 cases from 30 provinces within mainland China. Of these, 15.7 percent were classified as severe, and 6.1 percent had a primary endpoint, defined as ICU admission, death or mechanical ventilation.^[32]

The presence of diabetes (severe versus non-severe disease, 16.2 versus 5.7 percent; primary endpoint versus no primary endpoint, 26.9 versus 6.1 percent), hypertension (23.7 versus 13.4 percent; 35.8 versus 13.7 percent), or CHD (5.8 versus 1.8 percent; 9 versus 2 percent) was pointedly more common among patients with severe disease versus non-severe disease and with a primary endpoint versus no primary endpoint [33]. In a report of 191 patients in Wuhan province who were identified before January 31, 2020, there were significant univariate associations with death outcome for diabetes (31 versus 14 percent, $p = 0.005$), hypertension (48 versus 23 percent, $p = 0.0008$), and CHD (24 versus 1 percent, $p < 0.0001$).^[34]

The presence of acute injury determined by troponin elevation was a significant factor in the association of CVD and mortality. Among 187 patients with confirmed COVID-19, a history of CVD (defined as CHD, hypertension, or cardiomyopathy) was present in 66 (35 percent), and troponin was elevated in 52 (28 percent).^[35] Troponin elevation was more common in patients with CVD (55 percent, 36 of 66). Among patients with CVD and elevated troponin, the mortality rate was 69 percent (25 of 36). Furthermore, troponin elevation correlated with elevations in C-reactive protein, and higher troponin elevations predicted higher mortality.^[36] Though the number of patients included limits the interpretation, there is a recommendation that patients with causal CVD (including hypertension) are both at higher risks for acute injury and worsened survival in the setting of injury.^[37] The cause of this association and whether injury indicates increased risk for myocardial infarction will need further investigation. Until more data with larger numbers of patients are available, it seems reasonable to consider all patients with history of CVD, hypertension, or diabetes at higher risk.^[38] This risk is considered to be likely to be highest for patients with these risk factors, older age, known history of heart failure, or clinically significant valvular disease. For now, there are no specific measures based on this risk stratification, but it is advised that all of our patients with these risk factors to be especially cautious regarding

public health measures of social distancing, including with close family members. Furthermore, given the association with more severe disease and increased risk for acute myocardial injury, it is advised early clinical evaluation for any suspect symptoms.^[39]

1.7 Clinical Manifestations

The vast majority of patients presenting with a systemic illness consistent with COVID-19 will not have symptoms or signs of CAD. Patients may be tachycardic (with or without palpitations) in the setting of other illness-related symptoms.^[40] In patients with COVID-19, the clinical manifestations of acute CAD are likely similar to those without the virus. Few hospitalized COVID-19 patients have complained of chest pain on admission, but the true prevalence and characteristics of chest pain among COVID-19 patients are unknown. Physicians report that there are fewer ACS patients presenting to the hospital during the pandemic. In addition, there is concern that patients with ACS are presenting later to emergency departments due to fear of coronavirus exposure.^[41]

Such patients may suffer preventable mortality and morbidity without appropriate ACS management.^[42] Health care providers should make every effort to persuade patients with complaints suggestive of ACS to seek right assessment while confirming that appropriate protection and screening are available to avoid patient and provider concerns regarding nosocomial spread of the infection. If admitted, it is prudent to screen all patients for signs of coronavirus (e.g., fever, gastrointestinal disturbance, dyspnea, sore throat, and cough) regardless of the primary complaint. The pandemic varies in terms of intensity between regions. There are epicenters with extreme COVID-19-associated disease burden, whereas other areas continue to see more regular ACS and only rarely COVID-19 patients.^[43]

1.8 Pathophysiology of Cardiovascular Involvement in COVID-19

One of the most likely reasons of myocardial infarction is viral infection, which is commonly acknowledged. Acute heart injury incidents were identified in 12 percent to 8% of COVID-19 cases, with the rate being about 13 times higher in ICU/severe patients compared to non-ICU/severe patients.^[2] Patients who died had higher myoglobin, serum ferritin, C-reactive protein (CRP), troponin, and interleukin-6 levels among one hundred and fifty patients with laboratory-confirmed COVID-19 (IL-6). Any patients expired of fulminant myocardial infarction or "cytokine storm syndrome" caused by the virus, implying a high inflammatory load in COVID-19 and a potential rise in myocardial infarction-related cardiac events. COVID-19-induced fulminant myocarditis is also characterised by a powerful cytokine storm. In rare cases, acute heart damage is often detected by elevated high-sensitivity troponin levels.^[1]

High level of cardiac troponin T (TnT) (10%) and N-terminal pro-brain natriuretic peptides (NT-proBNP) (27.5%) were linked to significantly increased plasma IL6 levels in a sample of 120 SARS-CoV-2-infected patients. According to Guo *et al.*, 28 percent of 187 COVID-19 patients admitted had an acute myocardial infarction (elevated TnT).^[4] Inflammatory biomarkers like lymphopenia, leukocytosis, CRP, dimer, and procalcitonin were also higher in patients with elevated TnT levels. In COVID-19, myocardial damage is a

significant prognostic factor that is closely linked to mortality. SARS-CoV-2 tends to cause myocardial infarction by affecting the myocardium. Infection-related myocardial infarction and ischemia are likely to cause myocardial damage. The myocardium infiltration through mononuclear interstitial inflammatory cells has been observed in sporadic autopsy cases, especially in cases of fulminant myocardial infarction. To decide if corticosteroids are effective in reducing myocardial allergic reaction, further research is required.^[3]




Figure 3. Pathophysiology of COVID-19 with Myocardial Infarction.

Presently, the precise pathophysiology of SARS-CoV-2-related myocardial infarction is unknown. Proposed pathways include: (1) direct virus-induced, (2) autoimmune-mediated, and (3) immune-mediated, depending on host-related factors *i.e.*; infection phase (acute, subacute, or chronic) and (virus-host interactions).^[44] Both acquired immune responses and endogenous lead to myocardial damage in immune-mediated myocardial infarction, resulting in dilated cardiomyopathy. Despite this process, major studies of immunosuppressive drugs including prednisone and azathioprine have failed to demonstrate a meaningful therapeutic benefit; nevertheless, there is some indication that other immunomodulation techniques may be efficient.^[6]

Following virus-mediated damage, cryptic antigens from cardiac myocytes that are usually secluded from the immune system can be released, resulting in autoimmune-mediated myocardial infarction.^[45] There is also evidence to support the idea that autoimmune reactions are triggered by molecular mimicry involving epitopes exchanged by cardiac myosin, viral capsid

proteins, and other unspecified proteins on the cardiac myocyte's surfaces. When viruses escape the innate immune system, they replicate and produce viral proteins that promote cellular apoptosis and necrosis, resulting in direct myocardial injury. In humans, SARS-CoV-2 causes myocarditis through a mechanism close to that of other viral pathogens.^[46]

1.9 COVID-19-related Myocardial Infarction and Arrhythmias Mechanism

Arrhythmia is an important and potential clinical indication in COVID-19 patients. One retrospective analysis of COVID-19 patients' patient features in Hubei, China, found that 7.3 percent of the 137 patients had heart palpitations.^[47] Furthermore, arrhythmia was cited as a reason for ICU transfer in 44.4 percent of COVID-19 patients by Wang *et al.* When analysing these results, use caution because the sample size is small and therefore vulnerable to overestimation. Since the precise nature of the arrhythmias was seldom mentioned, it was difficult to determine if they were caused by other factors such as electrolyte deficiency or pre-existing arrhythmias.^[48] As a result, the true rate of arrhythmias

in COVID-19 patients is uncertain. Arrhythmias may, however, occur in the sense of a myocardial infarction. Approximately 78.7% of myocardial infarction patients have ventricular arrhythmia of any kind. Arrhythmias

have different characteristics in active and healed myocarditis, implying that the pathophysiology differs depending on the level of myocardial injury.^[49]




Figure 4. COVID-19–related Myocardial Infarction and Arrhythmias.

In SARS-CoV-2 cases, the arrhythmias pathophysiology comprises the following: (1) specific injuries to cardiomyocytes, interrupting the plasma membrane and electrochemical pathways; (2) pericardium infection, resulting in massive edoema,^[50] (3) ischemia from microvascular disease caused by possible pericytes infection; (4) re-entrant arrhythmias caused by myocardial fibrosis or scarring; and (5) proinflammatory situations 1, 2, and 3 may occur during an acute myocardial infarction, while situations 4 and 5 may occur during a chronic or healed myocardial infarction. In situation 5, proinflammatory cytokines (e.g., IL-6) can cause the cardiomyocyte membrane to lose plakoglobin, a desmosomal protein.^[51]

This may be arrhythmogenic, since it is hypothesized that insufficient cell-to-cell adhesion damages the cell membrane, resulting in fibrofatty replacement and death of cardiac cells.^[52] Additionally, decreased desmosomal protein surface expression is a recognised cause of arrhythmogenic cardiomyopathies. There is now substantial evidence that COVID-19 patients, particularly those with extreme presentations, have an increase in serum IL-6. As a result, it is possible that infection with SARS-CoV-2 causes arrhythmias in patients who have a genetic predisposition. Doctors must be cautious for arrhythmias, particularly in areas with a high COVID-19 burden and an increasing proportion of arrhythmogenic cardiomyopathy, such as Italy's north-eastern (Veneto) zone.^[53]

1.10 Prevention and Management

The best way to treat myocardial damage caused by COVID-19 has yet to be decided. Supportive treatment (including control of HF, medication for arrhythmias, and avoidance of cardiotoxins) is used to treat patients with myocardial damage, including clinically suspected myocardial infarction.^[1] Patients with COVID-19 and HF or asymptomatic LV systolic dysfunction should receive standard therapy for these conditions including pharmacologic therapy, careful management of fluid balance, and advanced therapies as needed. Standard indications for an angiotensin receptor-neprilysin inhibitor, angiotensin converting enzyme (ACE) inhibitor, or angiotensin receptor blocker (ARB) in treatment of HF with reduced ejection fraction (and for the latter two drugs in treatment of hypertension) apply to patients with COVID-19.^[2] Although there has been speculation that elevated ACE2 levels caused by renin-angiotensin-aldosterone system inhibitors might impact susceptibility to SARS-CoV-2 because ACE2 is a receptor for this virus, there is no evidence that treatment with these drugs worsens the clinical course of SARS-CoV-2 infection.^[54]

While laboratory evidence of a marked inflammatory response similar to cytokine release syndrome is associated with critical and fatal illness in patients with COVID-19, no treatment has been identified for this syndrome. Investigational protocols using the interleukin-6 inhibitors tocilizumab and sarilumab are ongoing.^[4] As suggested by International Society for

Heart and Lung Transplantation (ISHLT) guidance, ventricular assist device (VAD) implantation may be limited to INTERMACS status 1 to 3 patients based upon on local resource considerations during the COVID-19 pandemic. Patients with COVID-19 supported by LV assist devices (LVADs) may present with low-flow alarms due to vasodilation coupled with diarrhea and dehydration, which can occur with COVID-19. However, vigorous fluid resuscitation can result in right HF in these LVAD patients.^[3]

According to ISHLT recommendations, cardiac transplantation patients with active SARS-CoV-2 disease are put on the waitlist as inactive. Candidates for cardiac transplantation who recover from COVID-19 must wait at least 14 days after initial assessment and demonstrate two consecutive negative polymerase chain reaction-based assessments at least 48 hours ago.^[5] Management of cardiac transplantation recipients who develop COVID-19 is based upon the severity of illness. Heart transplantation recipients with mild COVID-19 (no shortness of breath or hypoxia) are generally managed by quarantine at home for two weeks and continuation of baseline maintenance immunosuppression with frequent follow-up to monitor for worsening symptoms.^[6]

1.11 Heart transplantation

Heart transplantation recipients with severe disease (respiratory failure needful ventilator support, admission to intensive care unit, acute respiratory distress syndrome, acute kidney failure, circulatory collapse, cardiomyopathy, and clinical syndrome well-matched with cytokine storm) or moderate disease (hypoxia or short breath requiring additional oxygen through nasal cannula) are treated with in-hospital supportive care.^[40] Many heart transplantation centers reduce (or hold) antiproliferative agents (e.g., mycophenolate mofetil or azathioprine) in heart transplantation recipients hospitalized with COVID-19 with close monitoring for rejection; generally, calcineurin inhibitors and prednisone doses have been maintained in this setting.^[36]

1.12 Antiviral therapy

Treatment guidelines for COVID-19 should be beyond the reach of the current study, given the numerous ongoing clinical trials and fast publication of new results.^[9] The most effective antiviral agent against SARS-CoV-2 is Remdesivir, a nucleotide correspondent prodrug that prevents viral RNA-dependent RNA polymerases.^[42] Remdesivir had an intermediate retrieval time of 11 days related to 15 days in the placebo community in a worldwide study of 1063 patients who were randomly assigned. In adults hospitalised with a lower respiratory tract infection and coronavirus, antiviral (remdesivir) was found to be superior to placebo in reducing the time to recover.^[8] Significant clinical improvement in clinical improvement in randomized, double-blind, placebo-controlled, multi-center studies of 237 adult patients hospitalized for the highly coronavirus in ten hospitals in Hubei, China.^[10] Clinical progress was

observed in 36 of 53 patients treated with considerate remdesivir in a regional cohort of 53 patients (22 in the Canada, Europe or US, and 9 in Japan) hospitalised for extreme coronavirus (68 percent). The clinical significance of the findings is unknown, as the authors acknowledge.^[11] To further explain the uncertainties surrounding remdesivir therapeutic efficiency and best practice, further large-scale randomised and placebo-controlled experiments are needed.^[7]

2. CONCLUSION

As a result of COVID-19's the high inflammatory risk, SARS-CoV-2 can either cause new cardiac pathologies or worsen existing cardiovascular diseases. Independent factors associated with mortality include cardiac damage due to TnT, elevated troponin levels, heart failure due to elevated NT-proBNP, and myocardial infarction. In the presence of an elevated troponin level, the initiation of new life-threatening tachyarrhythmias should raise concerns about myocardial infarction. Increased troponin levels in the early stages of RV dysfunction can indicate a poorer clinical outcome. Owing to a more intense inflammatory response, the cardiovascular system is more severely affected in serious and critical situations (such as higher levels of procalcitonin, ferritin, IL-6, and CRP). In severe patients with clinical worsening of hypoxia and hemodynamic dysfunction and a d-dimer greater than 36 times the upper normal limit, venous thromboembolism should be considered. Remdesivir, IL-6 blockers including anti-platelet therapy and tocilizumab can be used as needed, and patients with underlying cardiovascular conditions can continue to take an ACEI or ARB.

REFERENCES

1. S. De Rosa *et al.*, "Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era," *Eur. Heart J.*, 2020; 22: 2083–2088.
2. E. Mahmud *et al.*, "Management of acute myocardial infarction during the COVID-19 pandemic," *J. Am. Coll. Cardiol.*, 2020.
3. B. Long, W. J. Brady, A. Koyfman, and M. Gottlieb, "Cardiovascular complications in COVID-19," *Am. J. Emerg. Med.*, 2020.
4. F. A. Choudry *et al.*, "High thrombus burden in patients with COVID-19 presenting with ST-segment elevation myocardial infarction," *J. Am. Coll. Cardiol.*, 2020; 10: 1168–1176.
5. G. G. Stefanini *et al.*, "ST-elevation myocardial infarction in patients with COVID-19: clinical and angiographic outcomes," *Circulation*, 2020; 25: 2113–2116.
6. M. Roffi, G. Guagliumi, and B. Ibanez, "The obstacle course of reperfusion for ST-segment-elevation myocardial infarction in the COVID-19 pandemic," *Circulation*, 2020; 24: 1951–1953.
7. C.-C. F. Tam *et al.*, "Impact of coronavirus disease 2019 (COVID-19) outbreak on ST-segment-elevation myocardial infarction care in Hong Kong,

- China,” *Circ. Cardiovasc. Qual. Outcomes*, 2020; 4: e006631.
8. M. J. Daniels, M. G. Cohen, A. A. Bavry, and D. J. Kumbhani, “Reperfusion of ST-segment–elevation myocardial infarction in the COVID-19 era: business as usual?,” *Circulation*, 2020; 24, pp: 1948–1950.
 9. S. J. Wilson *et al.*, “Effect of the COVID-19 pandemic on ST-segment–elevation myocardial infarction presentations and in-hospital outcomes,” *Circ. Cardiovasc. Interv.*, 2020; 7: 009438.
 10. Z.-C. Jing, H.-D. Zhu, X.-W. Yan, W.-Z. Chai, and S. Zhang, “Recommendations from the Peking Union Medical College Hospital for the management of acute myocardial infarction during the COVID-19 outbreak,” *Eur. Heart J.*, 2020.
 11. J. Wu, M. A. Mamas, M. A. de Belder, J. E. Deanfield, and C. P. Gale, “Second decline in admissions with heart failure and myocardial infarction during the COVID-19 pandemic,” *J. Am. Coll. Cardiol.*, 2021; 8 pp: 1141–1143.
 12. M. D. Solomon *et al.*, “The Covid-19 pandemic and the incidence of acute myocardial infarction,” *N. Engl. J. Med.*, 2020; 7pp: 691–693.
 13. S. Garcia *et al.*, “Reduction in ST-segment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemic,” *J. Am. Coll. Cardiol.*, 2020; 22, pp: 2871–2872.
 14. F. Moroni *et al.*, “Collateral damage: medical care avoidance behavior among patients with myocardial infarction during the COVID-19 pandemic,” *Case Reports*, 2020; 10, pp: 1620–1624.
 15. J. Zeng, J. Huang, and L. Pan, “How to balance acute myocardial infarction and COVID-19: the protocols from Sichuan Provincial People’s Hospital,” *Intensive Care Med.*, 2020; 6, pp: 1111–1113.
 16. T. A. Hammad *et al.*, “Impact of COVID-19 pandemic on ST-elevation myocardial infarction in a non-COVID-19 epicenter,” *Catheter. Cardiovasc. Interv.*, 2021; 2 pp: 208–214.
 17. C. Loghin, S. Chauhan, and S. M. Lawless, “Pseudo-acute myocardial infarction in a young COVID-19 patient,” *Case Reports*, 2020; 9, pp: 1284–1288.
 18. G. Guagliumi, A. Sonzogni, I. Pescetelli, D. Pellegrini, and A. V. Finn, “Microthrombi and ST-Segment–Elevation Myocardial Infarction in COVID-19,” *Circulation*, 2020; 8, pp: 804–809.
 19. P. Dehghani *et al.*, “North American COVID-19 ST-Segment-Elevation Myocardial Infarction (NACMI) registry: rationale, design, and implications,” *Am. Heart J.*, 2020; 227 pp: 11–18.
 20. Y. Ueki, T. Otsuka, S. Windecker, and L. Räber, “ST-elevation myocardial infarction and pulmonary embolism in a patient with COVID-19 acute respiratory distress syndrome,” *Eur. Heart J.*, 2020; 22, p: 2134.
 21. M. Gramegna *et al.*, “ST-Segment–Elevation Myocardial Infarction During COVID-19 Pandemic: Insights From a Regional Public Service Healthcare Hub,” *Circ. Cardiovasc. Interv.*, 2020; 009413.
 22. O. Rodriguez-Leor and B. Cid-Alvarez, “ST-segment elevation myocardial infarction care during COVID-19: losing sight of the forest for the trees.” American College of Cardiology Foundation Washington DC, 2020.
 23. M. Hinterseer *et al.*, “Acute myocardial infarction due to coronary stent thrombosis in a symptomatic COVID-19 patient,” *Clin. Res. Cardiol.*, 2020; pp: 1–5.
 24. U. N. Khot *et al.*, “Impact of COVID-19 Pandemic on Critical Care Transfers for ST-Segment–Elevation Myocardial Infarction, Stroke, and Aortic Emergencies,” *Circ. Cardiovasc. Qual. Outcomes*, 2020; 006938.
 25. B. Popovic, J. Varlot, P. A. Metzendorf, H. Jeulin, F. Goehringer, and E. Camenzind, “Changes in characteristics and management among patients with ST-elevation myocardial infarction due to COVID-19 infection,” *Catheter. Cardiovasc. Interv.*, 2021; pp: 319–326.
 26. J. Mesnier *et al.*, “Hospital admissions for acute myocardial infarction before and after lockdown according to regional prevalence of COVID-19 and patient profile in France: a registry study,” *Lancet Public Heal.*, 2020; 10, pp: 536–542.
 27. J. Kirtane and S. Bangalore, “Why Fibrinolytic Therapy for ST-Segment–Elevation Myocardial Infarction in the COVID-19 Pandemic Is Not Your New Best Friend,” *Circ. Cardiovasc. Qual. Outcomes*, 2020; 6 p: 006885.
 28. S. Kitahara *et al.*, “COVID-19 pandemic is associated with mechanical complications in patients with ST-elevation myocardial infarction,” *Open Hear.*, 2021; 1, p: 001497.
 29. S. J. Reinstadler *et al.*, “Effect of the COVID-19 pandemic on treatment delays in patients with ST-segment elevation myocardial infarction,” *J. Clin. Med.*, 2020; 7, p: 2183.
 30. B. Metzler, P. Siostrzonek, R. K. Binder, A. Bauer, and S. J. Reinstadler, “Decline of acute coronary syndrome admissions in Austria since the outbreak of COVID-19: the pandemic response causes cardiac collateral damage,” *Eur. Heart J.*, 2020; 19, pp: 1852–1853.
 31. M. M. Mafham *et al.*, “COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England,” *Lancet*, 2020; 381–389.
 32. T. Lacour, C. Semaan, T. Genet, and F. Ivanec, “Insights for increased risk of failed fibrinolytic therapy and stent thrombosis associated with COVID-19 in ST-segment elevation myocardial infarction patients,” *Catheter. Cardiovasc. Interv.*, 2021; 241–243.
 33. J. Solano-López *et al.*, “Risk factors for in-hospital mortality in patients with acute myocardial infarction during the COVID-19 outbreak,” *Rev. Española Cardiol. (English E)*, 2020; 12: 985–993.

34. N. Cosentino, A. L. Bartorelli, and G. Marenzi, "Time to treatment still matters in ST-elevation myocardial infarction: a call to maintain treatment effectiveness during the COVID-19 pandemic," *Eur. Hear. Journal-Cardiovascular Pharmacother.*, 2020; 6: 408–409.
35. C. S. Kwok *et al.*, "Impact of COVID-19 on percutaneous coronary intervention for ST-elevation myocardial infarction," *Heart*, 23; 1805–1811.
36. M. Bansal, "Cardiovascular disease and COVID-19," *Diabetes Metab. Syndr. Clin. Res. Rev.*, 2020; 3: 247–250.
37. Z. Armaly, S. Kinaneh, and K. Skorecki, "Renal Manifestations of Covid-19: Physiology and Pathophysiology," *J. Clin. Med.*, 2021; 6: 1216.
38. M. Jasti, K. Nalleballe, V. Dandu, and S. Onteddu, "A review of pathophysiology and neuropsychiatric manifestations of COVID-19," *J. Neurol.*, 2020; 1–6.
39. S. Behzad, L. Aghaghazvini, A. R. Radmard, and A. Gholamrezanezhad, "Extrapulmonary manifestations of COVID-19: Radiologic and clinical overview," *Clin. Imaging*, 2020.
40. P. T. Kariyanna *et al.*, "Apical Takotsubo cardiomyopathy in a COVID-19 patient presenting with stroke: a case report and pathophysiologic insights," *Am. J. Med. case reports*, 2020; 350.
41. Gupta *et al.*, "Extrapulmonary manifestations of COVID-19," *Nat. Med.*, 2020; 7: 1017–1032.
42. L. Ortega-Paz, D. Capodanno, G. Montalescot, and D. Angiolillo, "COVID-19 Associated Thrombosis and Coagulopathy: Review of the Pathophysiology and Implications for Antithrombotic Management," *J. Am. Heart Assoc.*, 2021.
43. D. Atri, H. K. Siddiqi, J. Lang, V. Nauffal, D. A. Morrow, and E. A. Bohula, "COVID-19 for the cardiologist: a current review of the virology, clinical epidemiology, cardiac and other clinical manifestations and potential therapeutic strategies," *JACC Basic to Transl. Sci.*, 2020.
44. N. Kochi, A. P. Tagliari, G. B. Forleo, G. M. Fassini, and C. Tondo, "Cardiac and arrhythmic complications in patients with COVID-19," *J. Cardiovasc. Electrophysiol.*, 2020; 5: 1003–1008.
45. V. Thakur *et al.*, "Multi-organ involvement in COVID-19: beyond pulmonary manifestations," *J. Clin. Med.*, 2021; 10: 446.
46. B. P. Dhakal, N. K. Sweitzer, J. H. Indik, D. Acharya, and P. William, "SARS-CoV-2 infection and cardiovascular disease: COVID-19 heart," *Hear. Lung Circ.*, 2020.
47. J. M. T. G. y Galán, "Stroke as a complication and prognostic factor of COVID-19," *Neurol. (English Ed.)*, 2020.
48. Gulati *et al.*, "A comprehensive review of manifestations of novel coronaviruses in the context of deadly COVID-19 global pandemic," *Am. J. Med. Sci.*, 2020.
49. S. Bhaskar *et al.*, "Cytokine storm in COVID-19—immunopathological mechanisms, clinical considerations, and therapeutic approaches: the REPROGRAM consortium position paper," *Front. Immunol.*, 2020; 1648.
50. Magadam and R. Kishore, "Cardiovascular Manifestations of COVID-19 Infection," *Cells*, 2020; 11: 2508.
51. S. Kaur *et al.*, "The looming storm: blood and cytokines in COVID-19," *Blood Rev.*, 2020; 100743.
52. P. Atluri, D. Vasireddy, and S. Malayala, "COVID-19 encephalopathy in adults," *Cureus*, 2021.
53. Akhmerov and E. Marbán, "COVID-19 and the heart," *Circ. Res.*, 2020; 1443–1455.
54. K. M. Capaccione, J. S. Leb, B. D'souza, P. Utukuri, and M. M. Salvatore, "Acute myocardial infarction secondary to COVID-19 infection: A case report and review of the literature," *Clin. Imaging*, 2020.